Unknown

Dataset Information

0

Chromosome X aneusomy and androgen receptor gene copy number aberrations in apocrine carcinoma of the breast.


ABSTRACT: Carcinomas with apocrine differentiation (CAD) of the breast are rare tumours typically presenting high immunohistochemical expression of androgen receptor (AR) which is a target molecule for personalised therapy. To date, no studies have evaluated the genetic changes that are associated with AR immunohistochemical expression in CADs. The present work aims to characterise AR status in CADs. Twenty CAD tumours were studied with immunohistochemistry, in situ fluorescence hybridization and DNA methylation analysis, to evaluate AR expression and its regulator status. All tumours demonstrated high AR immunohistochemical expression, with over 95% of the neoplastic cells showing AR positivity in 19/20 cases. CADs showed AR gene copy loss in a percentage of neoplastic cells ranging from 5 to 84% (mean 48.93%). AR regulator genes, including the MAGE family, UXT and FLNA, presented variable methylation levels, but were mainly hypomethylated and therefore all transcriptionally active. The results of this study indicate that CADs present AR monosomy, paralleled by higher transcriptional activity of the gene with potential to influence response to AR deprivation therapy.

SUBMITTER: Cremonini A 

PROVIDER: S-EPMC8364532 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chromosome X aneusomy and androgen receptor gene copy number aberrations in apocrine carcinoma of the breast.

Cremonini Anna A   Saragoni Luca L   Morandi Luca L   Corradini Angelo G AG   Ravaioli Caterina C   Di Oto Enrico E   Limarzi Francesco F   Sanchez Alejandro M AM   Cucchi Maria C MC   Masetti Riccardo R   Quinn Cecily C   Foschini Maria P MP  

Virchows Archiv : an international journal of pathology 20210203 2


Carcinomas with apocrine differentiation (CAD) of the breast are rare tumours typically presenting high immunohistochemical expression of androgen receptor (AR) which is a target molecule for personalised therapy. To date, no studies have evaluated the genetic changes that are associated with AR immunohistochemical expression in CADs. The present work aims to characterise AR status in CADs. Twenty CAD tumours were studied with immunohistochemistry, in situ fluorescence hybridization and DNA meth  ...[more]

Similar Datasets

| S-EPMC4694861 | biostudies-literature
| S-EPMC4161348 | biostudies-literature
| S-EPMC3160190 | biostudies-literature
| S-EPMC3321189 | biostudies-literature
| S-EPMC4996377 | biostudies-literature
| S-EPMC5054221 | biostudies-literature
| S-EPMC4445249 | biostudies-literature
| S-EPMC4527302 | biostudies-literature
| S-EPMC3547038 | biostudies-literature